Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 7, 2020; 26(29): 4218-4239
Published online Aug 7, 2020. doi: 10.3748/wjg.v26.i29.4218
Table 1 Time between completion of neoadjuvant therapy and first reassessment in watch and wait clinical studies
StudyPatients (n)Neoadyuvant therapy
Timing of assessment after CRT
Radiotherapy scheduleChemotherapy regimen
Habr-Gama et al[107], 20137054Gy/30CRT: 5-FU/LV CNCT: 5-FU/LV x310 wk
Araujo et al[128], 20155145 Gy/25 or 50, 40 Gy/28CRT: 5-FU or capecitabineNS
Smith et al[129], 20123250,4 Gy/28CRT: 5-FU or capecitabine4-10 wk
Dalton et al[127], 20121245 Gy/25CRT: capecitabine8 wk
Renehan et al[99], 201625945 Gy/25CRT: 5-FU or capecitabine≥ 8 wk
Appelt et al[5], 20155160 Gy/30 to tumor + 50 Gy/30 to LNsTegafur-uracil (UFT)6 wk
Vaccaro et al[130], 201620450.4 Gy/28CRT: 5-FU/LV8-12 wk
Lai et al[131], 201626745 Gy/25 or 54 Gy/30CRT: 5-FU/LV8-12 wk
Martens et al[98], 201614150.4 Gy/28 or 5 Gy/5CRT: 5-FU8-20 wk
Creavin et al[132],36250-54 Gy/30CRT: 5-FU6-8 wk